Ahead of his upcoming presentation at the CX Symposium in London, it is a great time to watch Xeltis Medical Advisory Board Member Professor Frans Moll speaking on the issue of PFAS within the context of the medical industry. Watch here for more info: youtu.be/eDAUignO1yQ?si…

Ahead of this week's CX Symposium in London, UK, we are pleased to highlight two presentations on Xeltis technology by esteemed vascular access KOLs Prof Frans Moll & Luis Loureiro, MD. #vascularaccess #dialysis #CX2025

Our CEO Eliane Schutte attended the LSX World Congress where she participated in a panel discussion on emerging markets Read the BioWorld MedTech article here for insights from Eliane and other industry leaders on the potential of global expansion: rb.gy/t3ccvp

The Xeltis team will be attending the VASA 2025 Practicum, from May 16–17, in St. Louis, Missouri. We will be hosting a cannulation workshop where participants can observe how #aXess is redefining vascular surgery. #VascularAccess #VASA2025

Last week the Xeltis team attended VASA 2025 Practicum, from 16 - 17 May in St. Louis, Missouri. We hosted a cannulation workshop where participants could observe our cannulation technique, while KOL, Dr Karl Illig gave an update on our ongoing pivotal study in the EU and US.

From 21st - 22nd of May, Xeltis hosted an aXess conduit masterclass alongside Prof. Loreto Guesaldo at the Policlinico di Bari in Italy Nurses, nephrologists, and surgeons involved in the aXess EU pivotal trial had the opportunity to discuss and learn more about #aXess

Xeltis CEO Eliane Schutte shared her insights with pharmaphorum following her attendance and panel participation at the recent LSX World Congress. You can read the full article here: pharmaphorum.com/market-access/…

On June 5th, Xeltis brought together a small group of leading European dialysis nurses in vascular access with our clinical development team to share insights on how to enhance healthcare professional training, education, and patient communication for #aXess

Xeltis CEO Eliane Schutte spoke with Shani Alexander of BioWorld News on last week's positive data announcement for #Xabg, our coronary artery bypass (CABG) conduit. "It's early, but ... this is going to blow everybody's mind", said Eliane. bit.ly/40xKbG1

Last week, Prof Frans Moll attended ASVS 2025 in Singapore. He delivered a presentation titled 'Bioabsorbable conduits for Bypasses' which explored Xeltis' transformative vascular implants Visit our website to learn more: xeltis.com #ASVS #aXess #VascularAccess

Our CEO, Eliane Schutte, and CFO, Alexander Goemans, will be heading to London to attend LSI Europe from the 9th - 12th of September! Eliane will deliver a company presentation and will join a panel discussion alongside other leaders in the medtech industry. LSI - Life Science Intelligence™

We are proud to share that our CEO Eliane Schutte has been shortlisted for both CEO of the Year and Women Led Business Leader of the year, while Xeltis is a finalist for Medtech Company of the year at the 2025 European European Lifestars Awards! #EuropeanLifestars #Awards

Today Xeltis’ CFO Alexander Goemans will be joining a panel discussion at BioWin Days in Namur, Belgium. 🎤Interactive Panel - funding health innovation: Two startups journeys, two investor perspectives 📅 Tuesday 23 September 🕰️13:40 → 14:30 CET #BioWinDays

This week Xeltis is in Istanbul, Turkey, for the ESVS Annual Meeting Esteemed vascular access KOL and investigator Augusto Ministro will present the complete results from the successful EU pivotal Trial 📅 Tuesday 23 September 🕰️ 16:00 – 16:06 GMT +3 📍 Plenary 2B

Xeltis is proud to announce exceptional clinical data from its EU pivotal trial of aXess, its restorative vascular access conduit, underscoring aXess’ transformative potential in hemodialysis treatment. Read the full press release here: xeltis.com/xeltis-poised-…

This week, our CEO Eliane Schutte, CMO Paulo Neves, and VP of Clinical Business Development Luc Verhees, will be attending the EACTS Annual Meeting! The team is looking forward to connecting with the global surgical cardiothoracic community. Get in touch to connect!

This week, Xeltis attended the 53rd EDTNA/ERCA international conference in Porto, Portugal. Luca Silvagni, Senior Clinical Specialist, delivered a presentation on the early clinical experience of #aXess and the team hosted a cannulation workshop to simulate aXess cannulation